Trial · NCT06747130
Efficacy of Montelukast in Preventing Transaminase Elevation in Adult Dengue Patients
NCT06747130, Phase 2, Phase 3, Recruiting, Phramongkutklao College of Medicine and Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy of Montelukast in Preventing Transaminase Elevation in Adult Dengue Patients. Trials, record NCT06747130. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06747130
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of Montelukast in Preventing Transaminase Elevation in Adult Dengue Patients
- NCT number
- NCT06747130
- Status
- Recruiting
- Phases
- Phase 2, Phase 3
- Enrollment
- 82 participants, estimated
- Lead sponsor
- Phramongkutklao College of Medicine and Hospital
- Conditions
- Dengue, Montelukast, Transaminases
- Interventions
- Montelukast, Montelukast Placebo
- First posted
- 2024-12-24
- Last updated
- 2025-05-29
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Serum transaminase levels on the recovery day | From enrollment to the end of treatment at 10 days | Serum alanine transaminase and aspartate transaminase level will be measured at admission, and on every morning afterwards until the subject is discharged. The proportion of subjects with abnormal serum transaminase levels will be compared. The recovery day is defined as the day the participant was discharged from the hospital. |
| Secondary | Proportion of subjects with abnormal serum transaminase levels on the recovery day | From enrollment to the end of treatment at 10 days | Serum alanine transaminase and aspartate transaminase level will be measured at admission, and on every morning afterwards until the subject is discharged. The proportion of subjects with abnormal serum transaminase levels will be compared. |
| Secondary | Length of stay | From enrollment to the end of treatment at 10 days | Duration from hospital admission to discharge will be compared. |
| Secondary | Changes in serum transaminase levels | From enrollment to the end of treatment at 10 days | The change in serum transaminase levels from baseline at admission will be compared. |
| Secondary | Rate of dengue with warning signs | From enrollment to the end of treatment at 10 days | Rate of a composite outcome including abdominal tenderness or pain, persistent vomiting, clinical fluid accumulation, mucosal bleeding, liver enlargement \>2cm, increase in hematocrit concurrent with decrease in platelet count |
| Secondary | Rate of severe dengue | From enrollment to the end of treatment at 10 days | Rate of a composite outcome including shock, fluid accumulation with respiratory distress, severe bleeding leading to hypotension or decreased hematocrit, liver transaminase \>1000, impaired consciousness, heart and other organ failure |
| Secondary | Rate of dengue shock | From enrollment to the end of treatment at 10 days | Rate of hypotension or the pulse pressure of ≤ 20 mm Hg |
| Secondary | Hematocrit and platelet | From enrollment to the end of treatment at 10 days | Hematocrit and platelet levels will be compared. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06747130
GET https://conductscience.org/api/trials/v1/NCT06747130/registered